- Home
- SPCE vs SKYE Comparison
SPCE vs SKYE Comparison
Compare SPCE & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPCE
- SKYE
- Stock Information
- Founded
- SPCE 2017
- SKYE 2012
- Country
- SPCE United States
- SKYE United States
- Employees
- SPCE N/A
- SKYE N/A
- Industry
- SPCE Transportation Services
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- SPCE Consumer Discretionary
- SKYE Health Care
- Exchange
- SPCE Nasdaq
- SKYE Nasdaq
- Market Cap
- SPCE 174.9M
- SKYE 172.9M
- IPO Year
- SPCE N/A
- SKYE N/A
- Fundamental
- Price
- SPCE $5.84
- SKYE $5.84
- Analyst Decision
- SPCE Hold
- SKYE Strong Buy
- Analyst Count
- SPCE 6
- SKYE 4
- Target Price
- SPCE $31.50
- SKYE $19.25
- AVG Volume (30 Days)
- SPCE 1.2M
- SKYE 174.2K
- Earning Date
- SPCE 08-07-2024
- SKYE 08-09-2024
- Dividend Yield
- SPCE N/A
- SKYE N/A
- EPS Growth
- SPCE N/A
- SKYE N/A
- EPS
- SPCE N/A
- SKYE N/A
- Revenue
- SPCE $10,742,000.00
- SKYE N/A
- Revenue This Year
- SPCE N/A
- SKYE N/A
- Revenue Next Year
- SPCE N/A
- SKYE N/A
- P/E Ratio
- SPCE N/A
- SKYE N/A
- Revenue Growth
- SPCE 175.51
- SKYE N/A
- 52 Week Low
- SPCE $5.27
- SKYE $1.44
- 52 Week High
- SPCE $54.60
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- SPCE 39.56
- SKYE 49.83
- Support Level
- SPCE $6.02
- SKYE $5.67
- Resistance Level
- SPCE $6.84
- SKYE $6.69
- Average True Range (ATR)
- SPCE 0.45
- SKYE 0.68
- MACD
- SPCE 0.01
- SKYE 0.10
- Stochastic Oscillator
- SPCE 6.48
- SKYE 43.40
About SPCE Virgin Galactic Holdings Inc.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures advanced air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.